Evidence map›Paper›PMID 34266783›Full record

ArticleNephrologie & therapeutique2021

[Kidney damage in COVID-19].

Stéphane Burtey, Marion Sallée

Open access · bronzeAbstract read
In one paragraph

Article in Nephrologie & therapeutique, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Stéphane BurteyAix Marseille Univ, Inserm, INRAE, C2VN, 13005 Marseille, France; Aix-Marseille Univ, Centre de néphrologie et transplantation rénale, Hôpital de la Conception, 147, boulevard Baille, 13005 Marseille, France. Electronic address: Stephane.burtey@univ-amu.fr.
Marion SalléeAix Marseille Univ, Inserm, INRAE, C2VN, 13005 Marseille, France; Aix-Marseille Univ, Centre de néphrologie et transplantation rénale, Hôpital de la Conception, 147, boulevard Baille, 13005 Marseille, France.
Hôpital de la Conception · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 is a disease caused by the RNA virus SARS-CoV-2. It is characterised by an attack mainly affecting the respiratory system. There is renal involvement which is characterised by three main types of damage, acute tubular necrosis occurring in the most severe cases, proximal tubulopathy which is a prognostic marker of the disease and segmental and focal hyalinosis occurring in a genetically predisposed terrain. The pathophysiology of SARS-CoV-2 renal involvement is not yet defined. The direct role of the virus is debated, whereas the cytokine storm and the hypoxic and thrombotic complications seem more important. The long-term outcome of the renal damage appears to be quite good. Long-term follow-up will allow us to say whether the renal damage is part of the long COVID.

Indexed as

Acute Kidney InjuryBiopsyCOVID-19COVID-19 VaccinesGlomerulosclerosis, Focal SegmentalHumansKidneyKidney Tubular Necrosis, AcuteCOVID-19 VaccinesAcute tubular necrosisCOVID-19Focal segmental glomerulosclerosisHyalinose segmentaire et focaleNécrose tubulaire aiguëProximal tubulopathySARS-CoV-2Tubulopathie proximale

Identifiers

PMID34266783
PMCPMC8221000
OpenAlexW3173174617

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.